U.S. Markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.33-0.03 (-0.07%)
At close: 4:00PM EDT

Royalty Pharma plc

110 East 59th Street
Floor 33
New York, NY 10022
United States
212 883 0200
http://www.royaltypharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Pablo Gerardo LegorretaFounder, Chairman & CEO55.67MN/A1965
Mr. Terrance P. CoyneExec. VP & CFO3.4MN/AN/A
Dr. James Folmar Reddoch Ph.D.Exec. VP, Chief Scientific Officer and Co-Head of Research & Investments3.4MN/A1970
Mr. George Wingate LloydExec. VP of Investments & Gen. Counsel3.4MN/A1960
Mr. Christopher HiteVice Chairman & Exec. VP3.8MN/A1968
Dr. Marshall Urist M.D., Ph.D.Exec. VP and Co-Head of Research & InvestmentsN/AN/AN/A
Mr. Sandy Balkin Ph.D.Sr. VP of Strategy & AnalyticsN/AN/AN/A
Ms. Sarah CataVP & TreasurerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.

Corporate Governance

Royalty Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.